Improving the Safety of Fluoropyrimidine-based Chemotherapy
Status:
Recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
In this study it will be determined whether the rate of severe toxicity associated with
fluoropyrimidine treatment (capecitabine or 5-fluorouracil) can be significantly diminished
by individualized dosing of fluoropyrimidines based on upfront phenotypic assessment of
dihydropyrimidine dehydrogenase (DPD) deficiency.